Novelix Pharmaceuticals Ltd. (TRIMURTHI) — Tipsheet

Novelix is selling 5% of itself to 18 investors for ₹6.84 cr.

Tipsheet Editorial — Thu, 04 Jun 2026 22:49:02 GMT

The board approved a preferential issue at ₹57 a share, a ₹47 premium to face value. Shareholder approval is needed by July 2026.

What’s new

Board approved a preferential allotment of 1.2 million shares to 18 non-promoter investors.
The issue price is ₹57 per share, a ₹47 premium over face value.
The raise equals about 4.8% of the company's ₹142 cr market cap.

Why it matters

For a nano-cap with a ₹142 crore market cap, ₹6.84 crore of fresh equity is a material event. It brings cash for the balance sheet but dilutes existing holders by roughly 5%. The company previously flagged a need for capital; this filing delivers the price and the buyers.

What we’re watching

Whether the stock trades near the ₹57 issue price ahead of the EGM.
The allocation details among the 18 investors once disclosed.
How the 'general corporate purposes' spending breaks down.

The full read

Novelix is selling about 5% of itself. The board approved a preferential issue of 1.2 million shares to 18 non-promoter investors at ₹57 apiece, a ₹47 premium to face value. That prices the company's equity at ₹6.84 crore of new money. For a firm with a market cap of ₹142 crore, that is 4.8% of its value converted into cash. The terms are clear. The money is for general corporate purposes, though the company has previously linked a capital raise to scaling production. The next step is a shareholder vote on July 1, 2026. The market now has the precise dilution math and the valuation of the new shares to weigh.

Primary source: BSE · NSE

Novelix signs German deal to commercialize Astaxanthin production

Tipsheet Editorial — Wed, 03 Jun 2026 15:47:26 GMT

The nano-cap pharmaceutical firm has locked in a partner to scale its antioxidant from pilot to commercial output, but no financial terms are disclosed.

What’s new

Novelix has signed an agreement with Germany's GMBU e.V. for commercial-scale production of Astaxanthin at its Hyderabad facility.
The deal follows successful pilot-scale production completed by October 2025.
The agreement contains no special rights, related-party transactions, or share issuance to the German partner.

Why it matters

For a ₹126-crore company, moving a high-value antioxidant from pilot to commercial production is a concrete step toward a new revenue stream in the nutraceutical market. The partnership validates the science. But the complete absence of financial terms, no investment size, revenue projections, or profit-sharing details, leaves the actual upside entirely unquantified.

What we’re watching

When Novelix discloses capital expenditure or timeline for the commercial ramp-up.
First revenue figures from Astaxanthin sales, which are not yet reflected in guidance.
Any expansion of the partnership's scope beyond the Hyderabad facility.

The full read

Novelix Pharmaceuticals, a nano-cap drug firm with a market capitalization of just ₹126 crore, has signed a deal with Germany's GMBU e.V. to commercialize production of Astaxanthin. The antioxidant is used in dietary supplements and cosmetics. This agreement moves the product from the pilot stage (completed by October 2025) to commercial-scale manufacturing at Novelix's Hyderabad facility. The filing is silent on all financial specifics: no investment amount, no revenue projections, no profit-sharing terms. It does confirm there are no special rights or related-party elements. For a company this size, a new revenue stream in nutraceuticals is meaningful. The open question is how much capital is required and when the first sales arrive. Without those numbers, this is a validated concept, not a valuation event.

Primary source: BSE · NSE

Novelix Pharmaceuticals preps another equity raise

Tipsheet Editorial — Mon, 01 Jun 2026 20:42:17 GMT

The board will meet to approve a preferential issue. It's the latest capital call from a nano-cap with a market cap of ₹131 cr and a history of frequent dilutive raises.

What’s new

Novelix Pharmaceuticals has intimated a board meeting to consider approving a new preferential issue.
The specific size, price, and terms are not yet disclosed, pending the board's decision.
The company has already completed multiple preferential allotments and warrant conversions.

Why it matters

The filing is procedural, but the pattern is the story. A nano-cap repeatedly returning to the equity market signals persistent funding needs and raises the likelihood of further dilution for existing holders. The actual impact, however, waits on the board's decision and the terms it sets.

What we’re watching

The board's decision on the issue's size, pricing, and investor.
Any discount to the current market price and the resulting dilution.
The company's stated use of proceeds, if provided.

The full read

Novelix Pharmaceuticals will hold a board meeting to approve a new preferential issue. The company's market capitalisation is just ₹131 crore, and it has already completed multiple preferential allotments and warrant conversions. This is the latest in a pattern of frequent equity raises, pointing to ongoing funding requirements and a high probability of further dilution. The filing itself is only a procedural intimation; the specific size, price, and terms remain unknown. The real test is what the board approves, and on what terms. Not yet.

Primary source: BSE · NSE

Novelix calls another board meeting to weigh a new preferential issue

Tipsheet Editorial — Mon, 25 May 2026 20:06:12 GMT

The nano-cap has already raised ₹13.9 crore via preferential allotment and ₹1.7 crore via warrant conversion earlier this year. A fresh issue would add to that.

What’s new

The board will meet to consider a new preferential issue of securities.
Novelix already raised ₹13.9 crore via preferential allotment in February and ₹1.7 crore via warrant conversion in March.
The meeting will also cover FY26 financial results and a warrant conversion allotment.

Why it matters

A ₹112 crore market cap company going back to the preferential-issuance well within the same fiscal year is the story. The specific size and terms are unknown, but the pattern points to a persistent funding need. The dilution risk for existing holders is the immediate consequence.

What we’re watching

The size and pricing of the new issue once the board decides.
The stated use of proceeds, especially given the recent capital infusions.
Any final terms for the pending warrant conversion allotment.

The full read

Novelix Pharmaceuticals is going back to its shareholders for more capital. Its board will meet to consider a new preferential issue, having already raised ₹13.9 crore via the same route in February and ₹1.7 crore through warrant conversion in March. For a company with a market cap of just ₹112 crore, the frequency of capital calls is the key detail. A fresh issue on top of the recent raises will stretch the cap table further. The size and terms are not yet known. The board will also cover FY26 results and the prior warrant allotment. The open question is what this latest raise will cost existing holders.

Primary source: BSE · NSE